Jove
Visualize
Contact Us

Related Concept Videos

FDA Approved Drugs: Changes to Approved Drugs01:26

FDA Approved Drugs: Changes to Approved Drugs

312
Post-approval, manufacturers may modify an approved new or generic drug product. Such modifications can encompass alterations in the Active Pharmaceutical Ingredient (API), manufacturing process, formulation, batch size, manufacturing site, and container closure system (FDA Guidance for Industry, April 2004). Often, a drug product may undergo multiple changes.These modifications require careful evaluation to determine their potential impact on the drug product's identity, strength, quality,...
312
Impact of Pharmacokinetic–Pharmacodynamic Models: Regulatory Decisions01:15

Impact of Pharmacokinetic–Pharmacodynamic Models: Regulatory Decisions

59
PK–PD modeling has significantly influenced FDA regulatory decisions, particularly drug approval, dosage optimization, and labeling. These models integrate pharmacokinetics (PK) and pharmacodynamics (PD) to predict drug behavior and effects, aiding in optimizing dosing regimens and enhancing the probability of clinical trial success.One notable example is Nesiritide (Natrecor®), a recombinant human brain natriuretic peptide for treating acute decompensated congestive heart failure...
59
Drug Regulation01:25

Drug Regulation

3.2K
Drug regulation encompasses the management of drug usage by evaluating its safety and efficacy through assessments conducted by regulatory authorities. Regrettably, the history of drug regulation is marred by several catastrophic events. One such incident is the Elixir Sulfanilamide tragedy, in which the toxic compound diethyl glycol was included in a sweet-tasting medication, leading to numerous fatalities. This event prompted the enactment of the Food, Drug, and Cosmetic Act in 1938. Under...
3.2K
Drug Administration and Therapy Phases: Overview01:26

Drug Administration and Therapy Phases: Overview

1.6K
Drugs, the chemical agents used in diagnosing, treating, or preventing diseases, undergo a four-phase process of development: pharmaceutic, pharmacokinetics, pharmacodynamics, and therapeutic.
The pharmaceutical phase focuses on leveraging the physicochemical properties of the drug to design and manufacture an effective product. Variants include orally administered tablets or capsules, topical creams or ointments, and parenteral-delivery solutions or emulsions.
The pharmacokinetic phase...
1.6K
Drug Products: Biologics, Biosimilars and Interchangeables01:28

Drug Products: Biologics, Biosimilars and Interchangeables

336
Biologics, derived from living sources such as humans, animals, or microorganisms, represent a significant category of pharmaceuticals. These complex molecules, developed through advanced biotechnological methods or purified from natural sources, include essential medical treatments like insulin and growth hormones. The complexity of biologics arises from their large molecular structures and the intricate processes required for their production, making them distinct from conventional...
336
Prescription, Nonprescription and Orphan Drugs01:02

Prescription, Nonprescription and Orphan Drugs

1.4K
Prescription drugs require a prescription from a medical practitioner and can only be obtained from a pharmacy. They have many applications, including treating pain, anxiety, and hypertension.
The misuse and addiction to prescription drugs is a growing problem that can affect people of all age groups, specifically teenagers. This can happen when prescription medications are used in ways not intended by the prescriber, such as taking someone else's prescription or using medication for...
1.4K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Pharmaceutical Approval Update.

P & T : a peer-reviewed journal for formulary management·2019
Same author

Pharmaceutical Approval Update.

P & T : a peer-reviewed journal for formulary management·2019
Same author

Pharmaceutical Approval Update.

P & T : a peer-reviewed journal for formulary management·2019
Same author

Pharmaceutical Approval Update.

P & T : a peer-reviewed journal for formulary management·2019
Same author

Pharmaceutical Approval Update.

P & T : a peer-reviewed journal for formulary management·2019
Same author

Pharmaceutical Approval Update.

P & T : a peer-reviewed journal for formulary management·2018
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Video

Updated: Mar 13, 2026

Author Spotlight: Microbial Control and Monitoring Strategies for Cleanroom Environments and Cellular Therapies
09:30

Author Spotlight: Microbial Control and Monitoring Strategies for Cleanroom Environments and Cellular Therapies

Published on: March 17, 2023

4.6K

Pharmaceutical Approval Update.

Michele B Kaufman

    P & T : a Peer-Reviewed Journal for Formulary Management
    |October 21, 2016
    PubMed
    Summary
    This summary is machine-generated.

    This summary covers three medications: obeticholic acid for primary biliary cholangitis, sofosbuvir/velpatasvir for hepatitis C, and daclizumab for multiple sclerosis. These treatments target distinct chronic and autoimmune conditions.

    More Related Videos

    Drug Repurposing Hypothesis Generation Using the "RE:fine Drugs" System
    05:10

    Drug Repurposing Hypothesis Generation Using the "RE:fine Drugs" System

    Published on: December 11, 2016

    10.3K
    Validation of Therapeutic Agent Conjugation to Polyvinyl Alcohol-Coated Medical Devices
    06:34

    Validation of Therapeutic Agent Conjugation to Polyvinyl Alcohol-Coated Medical Devices

    Published on: November 29, 2024

    667

    Related Experiment Videos

    Last Updated: Mar 13, 2026

    Author Spotlight: Microbial Control and Monitoring Strategies for Cleanroom Environments and Cellular Therapies
    09:30

    Author Spotlight: Microbial Control and Monitoring Strategies for Cleanroom Environments and Cellular Therapies

    Published on: March 17, 2023

    4.6K
    Drug Repurposing Hypothesis Generation Using the "RE:fine Drugs" System
    05:10

    Drug Repurposing Hypothesis Generation Using the "RE:fine Drugs" System

    Published on: December 11, 2016

    10.3K
    Validation of Therapeutic Agent Conjugation to Polyvinyl Alcohol-Coated Medical Devices
    06:34

    Validation of Therapeutic Agent Conjugation to Polyvinyl Alcohol-Coated Medical Devices

    Published on: November 29, 2024

    667

    Area of Science:

    • Hepatology
    • Virology
    • Neurology

    Background:

    • Primary biliary cholangitis (PBC) is a chronic liver disease.
    • Chronic hepatitis C virus (HCV) infection requires effective antiviral therapy.
    • Relapsing multiple sclerosis (RMS) is a debilitating autoimmune condition affecting the central nervous system.

    Purpose of the Study:

    • To review the efficacy and safety of obeticholic acid (Ocaliva) in treating PBC.
    • To assess the effectiveness of sofosbuvir 400 mg/velpatasvir 100 mg (Epclusa) for chronic HCV infection.
    • To evaluate daclizumab (Zinbryta) as a treatment option for RMS.

    Main Methods:

    • Literature review of clinical trials and real-world data for each medication.
    • Analysis of efficacy endpoints, including biochemical markers for PBC, viral clearance for HCV, and relapse rates for MS.
    • Safety profile assessment based on adverse event reporting.

    Main Results:

    • Obeticholic acid demonstrated improvements in liver biochemistry for PBC patients.
    • Sofosbuvir/velpatasvir achieved high sustained virologic response rates in chronic HCV infection.
    • Daclizumab showed a reduction in relapse rates for RMS, but with specific safety considerations.

    Conclusions:

    • Obeticholic acid is an important option for PBC management.
    • Sofosbuvir/velpatasvir offers a highly effective cure for chronic HCV.
    • Daclizumab provides a therapeutic option for RMS, necessitating careful patient selection and monitoring.